ALMRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Alamar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$26.30+1.02 (+4.03%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
35.1%
24M of 69M shares
Institutional holders
86
86 new, 0 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $8.00M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Qiming Corporate GP VI, Ltd | 7,066,573 | 10.20% | 13G (passive) | Jun 30, 2026 |
| Nicholas Naclerio | 6,363,612 | 9.60% | 13D (active) | Apr 20, 2026 |
| Daqing Cai | 4,972,134 | 7.20% | 13G (passive) | Apr 16, 2026 |
| Yuling Luo | 4,528,718 | 6.40% | 13G (passive) | Jun 30, 2026 |
| Sands Capital Alternatives, LLC | 4,230,926 | 6.30% | 13D (active) | Apr 16, 2026 |
| Sands Frank M. | 4,230,926 | 6.10% | 13D (active) amendment | Jul 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALMR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sands Capital Ventures, LLC | 4,230,926 | 6.10% | $114.62M | New | 18.68% |
| Samsara BioCapital, LLC | 2,480,310 | 3.57% | $67.19M | New | 5.52% |
| T. Rowe Price Investment Management, Inc. | 2,202,597 | 3.17% | $59.67K | New | 0.04% |
| ARK Investment Management LLC | 1,373,959 | 1.98% | $37.22M | New | 0.24% |
| Braidwell LP | 1,083,983 | 1.56% | $29.37M | New | 1.09% |
| Alliancebernstein L.P. | 1,003,077 | 1.45% | $27.17M | New | 0.01% |
| Hhlr Advisors, Ltd. | 956,462 | 1.38% | $25.91M | New | 3.11% |
| BlackRock, Inc. | 911,445 | 1.31% | $24.69M | New | 0.00% |
| Millennium Management LLC | 865,764 | 1.25% | $23.45M | New | 0.01% |
| FMR LLC | 829,424 | 1.20% | $22.47M | New | 0.00% |
| Pura Vida Investments, LLC | 755,909 | 1.09% | $20.48M | New | 123.99% |
| Emerald Advisers, LLC | 647,183 | 0.93% | $17.53M | New | 0.41% |
| Artisan Partners Limited Partnership | 613,744 | 0.88% | $16.63M | New | 0.03% |
| Deerfield Management Company, L.P. (Series C) | 600,000 | 0.86% | $16.25M | New | 0.17% |
| Vanguard Capital Management LLC | 463,385 | 0.67% | $12.55M | New | 0.00% |
| Farallon Capital Management LLC | 462,900 | 0.67% | $12.54M | New | 0.06% |
| Wellington Management Group Llp | 457,974 | 0.66% | $12.41M | New | 0.00% |
| Emerald Mutual Fund Advisers Trust | 422,127 | 0.61% | $11.44M | New | 0.40% |
| Ameriprise Financial Inc | 418,965 | 0.60% | $11.35M | New | 0.00% |
| Geode Capital Management, LLC | 330,134 | 0.48% | $8.95M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 24M | 35.1% | 86 / 0 | 0 / 0 | 24M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALMR | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 957,178 | 1.38% | $24.27M | 1.56% | Jul 31, 2026 |
| AB Small Cap Growth Portfolio | 445,297 | 0.64% | $12.06M | 0.39% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 355,864 | 0.51% | $9.64M | 0.10% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 345,768 | 0.50% | $7.07M | 0.19% | May 31, 2026 |
| iShares Russell 2000 ETF | 321,505 | 0.46% | $8.71M | 0.01% | Jun 30, 2026 |
| SmallCap Growth Fund I | 321,124 | 0.46% | $8.14M | 0.33% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 320,260 | 0.46% | $8.68M | 0.00% | Jun 30, 2026 |
| Select Health Care Portfolio | 300,000 | 0.43% | $6.13M | 0.11% | May 31, 2026 |
| Emerald Growth Fund | 280,435 | 0.40% | $7.11M | 0.48% | Jul 31, 2026 |
| Select Medical Technology and Devices Portfolio | 280,000 | 0.40% | $5.72M | 0.19% | May 31, 2026 |
| Artisan Small Cap Fund | 193,237 | 0.28% | $5.23M | 0.55% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 190,941 | 0.28% | $5.17M | 0.10% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 160,000 | 0.23% | $4.06M | 0.13% | Jul 31, 2026 |
| Emerald Growth Fund | 155,348 | 0.22% | $3.89M | 0.28% | Apr 30, 2026 |
| Fidelity Small Cap Index Fund | 144,686 | 0.21% | $3.67M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yuling Luo | Chief Executive Officer, Director | 5,888,675 | 8.49% | Apr 20, 2026 |
| Shiping Chen | Chief Operating Officer, Director | 1,445,770 | 2.08% | Apr 20, 2026 |
| John L. Brottem | General Counsel | 29,000 | 0.04% | Sep 16, 2026 |
| Timothy Ogden White | President | 491,803 | 0.71% | Apr 20, 2026 |
| Justin J. McAnear | Chief Financial Officer | 37,220 | 0.05% | Apr 20, 2026 |
| Robert P. Ragusa | Director | 5,686 | 0.01% | Sep 3, 2026 |
| Rebecca Chambers | Director | – | – | Apr 20, 2026 |
| Frank Witney | Director | – | – | Apr 20, 2026 |
| Ian W. Ratcliffe | Director | – | – | Apr 16, 2026 |
| Qiming GP VIII, LLC | 10% owner | – | – | Apr 22, 2026 |
| Qiming Venture Partners VI, L.P. | 10% owner | – | – | Apr 22, 2026 |
| Qiming Venture Partners VIII Investments, LLC | 10% owner | – | – | Apr 22, 2026 |
| Qiming GP VIII-HC, LLC | 10% owner | 185,163 | 0.27% | Apr 22, 2026 |
| Qiming Venture Partners VIII-HC, L.P. | 10% owner | – | – | Apr 22, 2026 |
| Qiming Corporate GP VI, Ltd. | 10% owner | – | – | Apr 22, 2026 |
| Qiming Managing Directors Fund VI, L.P. | 10% owner | – | – | Apr 22, 2026 |
| Nicholas Naclerio | 10% owner | 10,104,566 | 14.56% | Apr 20, 2026 |
| Illumina Innovation Fund II GP, L.L.C. | 10% owner | 507,076 | 0.73% | Apr 20, 2026 |
| Illumina Innovation Fund II, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Illumina Innovation Fund III GP, L.L.C. | 10% owner | – | – | Apr 20, 2026 |
| Illumina Innovation Fund III, L.P. | 10% owner | – | – | Apr 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John L. Brottem General Counsel | Sep 14, 2026 | Award | +29,000 | – | – | 29,000 |
| Robert P. Ragusa Director | Sep 1, 2026 | Award | +5,686 | – | – | 5,686 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | −1,922,329 | – | – | 0 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | −1,605,645 | – | – | 0 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | −6,881,410 | – | – | 0 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | −185,163 | – | – | 0 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Conversion | +1,922,329 | – | – | 1,922,329 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Conversion | +1,605,645 | – | – | 1,605,645 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Conversion | +6,881,410 | – | – | 6,881,410 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | +185,163 | – | – | 185,163 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | +6,881,410 | – | – | 6,881,410 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | +1,605,645 | – | – | 1,605,645 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Other | +1,922,329 | – | – | 1,922,329 |
| Qiming GP VIII-HC, LLC 10% owner | Apr 20, 2026 | Conversion | +185,163 | – | – | 185,163 |
| Shiping Chen Chief Operating Officer, Director | Apr 20, 2026 | Conversion | +72,853 | – | – | 722,885 |
| Shiping Chen Chief Operating Officer, Director | Apr 20, 2026 | Conversion | +320,511 | – | – | 650,032 |
| Shiping Chen Chief Operating Officer, Director | Apr 20, 2026 | Other | −722,885 | – | – | 0 |
| Shiping Chen Chief Operating Officer, Director | Apr 20, 2026 | Other | +722,885 | – | – | 722,885 |
| Shiping Chen Chief Operating Officer, Director | Apr 20, 2026 | Award | +37,220 | – | – | 760,105 |
| Timothy Ogden White President | Apr 20, 2026 | Award | +37,220 | – | – | 491,803 |
| Timothy Ogden White President | Apr 20, 2026 | Other | −454,583 | – | – | 0 |
| Timothy Ogden White President | Apr 20, 2026 | Other | +454,583 | – | – | 454,583 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Buy | +235,294 | $17.00 | $4.00M | 507,076 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Conversion | +271,782 | – | – | 271,782 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Other | −5,510,516 | – | – | 0 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Conversion | +922,152 | – | – | 5,510,516 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Conversion | +4,588,364 | – | – | 4,588,364 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Other | +5,510,516 | – | – | 5,510,516 |
| Illumina Innovation Fund II GP, L.L.C. 10% owner | Apr 20, 2026 | Conversion | +346,020 | – | – | 5,856,536 |
| Justin J. McAnear Chief Financial Officer | Apr 20, 2026 | Award | +37,220 | – | – | 37,220 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Conversion | +1,224,152 | – | – | 1,224,152 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Conversion | +1,386,746 | – | – | 1,499,797 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Other | −1,864,065 | – | – | 0 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Other | +1,224,152 | – | – | 1,224,152 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Other | −1,224,152 | – | – | 0 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Award | +76,509 | – | – | 1,940,574 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Other | +1,864,065 | – | – | 1,864,065 |
| Yuling Luo Chief Executive Officer, Director | Apr 20, 2026 | Conversion | +364,268 | – | – | 1,864,065 |
| Nicholas Naclerio Director | Apr 20, 2026 | Award | +5,686 | – | – | 5,686 |
| Nicholas Naclerio Director | Apr 20, 2026 | Other | +5,510,516 | – | – | 5,510,516 |
| Nicholas Naclerio Director | Apr 20, 2026 | Conversion | +4,588,364 | – | – | 4,588,364 |
| Nicholas Naclerio Director | Apr 20, 2026 | Conversion | +922,152 | – | – | 5,510,516 |
| Nicholas Naclerio Director | Apr 20, 2026 | Other | −5,510,516 | – | – | 0 |
| Nicholas Naclerio Director | Apr 20, 2026 | Conversion | +346,020 | – | – | 5,856,536 |
| Nicholas Naclerio Director | Apr 20, 2026 | Conversion | +271,782 | – | – | 271,782 |
| Nicholas Naclerio Director | Apr 20, 2026 | Buy | +235,294 | $17.00 | $4.00M | 507,076 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Qiming Venture Partners VIII-HC, L.P. Affiliate | Oct 14, 2026 | 435,468 | $10.24M | Oct 14, 2026 | Private investment in series C preferred shares; automatically converted into common stock upon IPO |
| Qiming Venture Partners VIII Investments, LLC Affiliate | Oct 14, 2026 | 363,729 | $8.56M | Oct 14, 2026 | Private investment in Series C preferred shares, automatically converted into common stock upon IPO |
| Qiming Managing Directors Fund VI, L.P. Affiliate | Oct 14, 2026 | 41,945 | $987.00K | Oct 14, 2026 | Private investment in Series A-3 preferred shares, automatically converted into common stock upon IPO |
| Qiming Venture Partners VI, L.P. Affiliate | Oct 14, 2026 | 1,558,858 | $36.66M | Oct 14, 2026 | Private investment in Series A-3 preferred shares, automatically converted into common stock upon IPO |